Cargando…

Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival

INTRODUCTION: Immune checkpoint inhibitors (ICI) are associated with unique immune-related adverse events (irAEs). Immune-related thrombocytopenia (irTCP) is an understudied and poorly understood toxicity; little data are available regarding either risk of irTCP or the effect of irTCP on clinical ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haddad, Tyler C., Zhao, Songzhu, Li, Mingjia, Patel, Sandip H., Johns, Andrew, Grogan, Madison, Lopez, Gabriella, Miah, Abdul, Wei, Lai, Tinoco, Gabriel, Riesenberg, Brian, Li, Zihai, Meara, Alexa, Bertino, Erin M., Kendra, Kari, Otterson, Gregory, Presley, Carolyn J., Owen, Dwight H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015999/ https://www.ncbi.nlm.nih.gov/pubmed/34618180 http://dx.doi.org/10.1007/s00262-021-03068-2

Ejemplares similares

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications
por: Spakowicz, Daniel, et al.
Publicado: (2020)

Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer
por: Johns, Andrew C, et al.
Publicado: (2023)

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers
por: Li, Mingjia, et al.
Publicado: (2019)

Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers
por: Jain, Natasha A, et al.
Publicado: (2020)

Emerging biomarkers for checkpoint inhibitors in thymic epithelial tumors
por: Owen, Dwight H., et al.
Publicado: (2019)

Too Many Appointments: Assessing Provider and Nursing Perception of Barriers to Referral for Outpatient Palliative Care
por: Agne, Julia L., et al.
Publicado: (2021)

Impact of an Embedded Palliative Care Clinic on Healthcare Utilization for Patients With a New Thoracic Malignancy
por: Gast, Kelly C., et al.
Publicado: (2022)

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors
por: Matsui, Jennifer K., et al.
Publicado: (2022)

Feasibility of an embedded palliative care clinic model for patients with an advanced thoracic malignancy
por: Bertino, Erin M., et al.
Publicado: (2023)

The Emerging Roles of Endoplasmic Reticulum Stress in Balancing Immunity and Tolerance in Health and Diseases: Mechanisms and Opportunities
por: Li, Anqi, et al.
Publicado: (2020)

Development of molecular and pharmacological switches for chimeric antigen receptor T cells
por: Wu, Bill X., et al.
Publicado: (2019)

RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity
por: Ansa-Addo, Ephraim A., et al.
Publicado: (2020)

Analysis of Patient Preferences in Lung Cancer – Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects
por: Janssen, Ellen M, et al.
Publicado: (2020)

Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With None–Small-cell Lung Cancer
por: Owen, Dwight H., et al.
Publicado: (2018)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017)

Is CD47 an innate immune checkpoint for tumor evasion?
por: Liu, Xiaojuan, et al.
Publicado: (2017)

Refractory dermatitis contributed by pityriasis versicolor: a case report
por: Li, Mingjia, et al.
Publicado: (2021)

Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022)

Immune Checkpoint-Related Gene Polymorphisms Are Associated With Primary Immune Thrombocytopenia
por: Wang, Shuwen, et al.
Publicado: (2021)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
por: Calvo, Roser
Publicado: (2019)

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
por: Yang, Yuanquan, et al.
Publicado: (2022)

Virtual Evolution of HVEM Segment for Checkpoint Inhibitor Discovery
por: Yu, Mingjia, et al.
Publicado: (2021)

Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor
por: Chong, Kah-Meng, et al.
Publicado: (2022)

Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review
por: Liu, Xiaolin, et al.
Publicado: (2020)

Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review
por: Xie, Wang, et al.
Publicado: (2021)

Experience with subcutaneous immunoglobulin therapy in two pediatric cases of immune thrombocytopenia purpura
por: Chapdelaine, H, et al.
Publicado: (2012)

Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer
por: O’Meara, Connor H., et al.
Publicado: (2023)

Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer
por: Leapman, Michael S., et al.
Publicado: (2020)

Primary Splenic Diffuse Large B-Cell Lymphoma: A Rare Case of Massive Splenomegaly and Thrombocytopenia
por: Khalid, Sidra, et al.
Publicado: (2018)

Advances in epigenetic therapeutics with focus on solid tumors
por: Jin, Ning, et al.
Publicado: (2021)

On Veratrum Viride
por: Otterson,
Publicado: (1861)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Sepsis: thrombocytopenia is bad, not recovering thrombocytopenia is too bad
por: Faviere, W, et al.
Publicado: (2011)

Thrombocytopenia in COVID-19 and vaccine-induced thrombotic thrombocytopenia
por: Geronikolou, Styliani A., et al.
Publicado: (2022)

Cyclic Thrombocytopenia: A Rare Cause of Recurrent Thrombocytopenia
por: Oyenuga, Mosunmoluwa, et al.
Publicado: (2022)

Immune thrombocytopenia
Publicado: (2011)

Management of thrombocytopenia
por: Izak, Marina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qlbnlilm4m4h3mhqog7vo0c65r